Payment overview · 2025
General Payments
$274.31
12 reported records · 7 companies
Healthcare provider profile · identity verified
John Robert Perkins, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ELK CITY, OK · NPI 1437141983
Verified facts
What the public records show
CMS Open Payments records show John Robert Perkins, M.D. received $274.31 in general payments during 2025 across 12 reported records.
PFIZER INC. accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Xyosted.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Xyosted by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $101.01 | 36.8% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.08 | 23.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $28.50 | 10.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $24.48 | 8.9% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $24.13 | 8.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.06 | 6.2% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $16.05 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $274.31 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $63.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.24 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $54.24 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.77 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.77 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.77 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $28.50 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 25 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 523 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 414 | 92 |
| Potassium Chloride | Potassium Chloride | 310 | 60 |
| Omeprazole | Omeprazole | 196 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 193 | 22 |
| Azithromycin | Azithromycin | 176 | 111 |
| Atorvastatin Calcium | Atorvastatin Calcium | 161 | 41 |
| Mounjaro | Tirzepatide | 149 | 19 |
| Eliquis | Apixaban | 142 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 32 |
| Tramadol Hcl | Tramadol Hcl | 134 | 21 |
| Ozempic | Semaglutide | 130 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 20 |
| Spironolactone | Spironolactone | 102 | 25 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 101 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 18 |
| Sertraline Hcl | Sertraline Hcl | 97 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 22 |
| Gabapentin | Gabapentin | 93 | 23 |
| Simvastatin | Simvastatin | 89 | 19 |
| Methotrexate | Methotrexate Sodium | 88 | 19 |
| Montelukast Sodium | Montelukast Sodium | 86 | 19 |
| Allopurinol | Allopurinol | 83 | 17 |
| Trazodone Hcl | Trazodone Hcl | 83 | 17 |
| Bupropion Xl | Bupropion Hcl | 82 | 18 |
| Amlodipine Besylate | Amlodipine Besylate | 79 | 19 |
| Losartan Potassium | Losartan Potassium | 79 | 19 |
| Meloxicam | Meloxicam | 78 | 22 |
| Pregabalin | Pregabalin | 78 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 74 | 36 |
| Synthroid | Levothyroxine Sodium | 72 | 12 |
| Eszopiclone | Eszopiclone | 71 | suppressed |
| Valsartan | Valsartan | 71 | 20 |
| Estradiol (Once Weekly) | Estradiol | 68 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 14 |
| Estradiol | Estradiol | 66 | 24 |
| Metformin Hcl | Metformin Hcl | 63 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | suppressed |
| Clonazepam | Clonazepam | 62 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 62 | 11 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 60 | 12 |
| Mupirocin | Mupirocin | 59 | 39 |
| Rybelsus | Semaglutide | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | suppressed |
| Prednisone | Prednisone | 54 | 13 |
| Furosemide | Furosemide | 53 | 14 |
| Lisinopril | Lisinopril | 51 | suppressed |
| Carvedilol | Carvedilol | 49 | 12 |
| Lorazepam | Lorazepam | 47 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 31 |
| Torsemide | Torsemide | 44 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 15 |
| Methylprednisolone | Methylprednisolone | 43 | 35 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 42 | suppressed |
| Telmisartan | Telmisartan | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 18 |
| Xyosted | Testosterone Enanthate | 38 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 37 | suppressed |
| Famotidine | Famotidine | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 17 |
| Levofloxacin | Levofloxacin | 35 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 19 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 12 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Febuxostat | Febuxostat | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Celecoxib | Celecoxib | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Atenolol | Atenolol | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Estrogel | Estradiol | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 19 | suppressed |
| Leflunomide | Leflunomide | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Desloratadine | Desloratadine | 18 | suppressed |
| Dotti | Estradiol | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 16 | 16 |
| Dutasteride | Dutasteride | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Armodafinil | Armodafinil | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humira(Cf) | Adalimumab | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Qtern | Dapagliflozin/Saxagliptin Hcl | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $274.31 · 12 records | PFIZER INC. | ABRYSVO, COMIRNATY, Flector, Licart, NURTEC ODT, PREVNAR 20, Quviviq, Symbravo, The Cologuard Plus Collection Kit, Tirosint, XYOSTED, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Antares Pharma, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error